KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Sales (2016 - 2025)

Novavax (NVAX) has 16 years of Return on Sales data on record, last reported at 0.12% in Q4 2025.

  • For Q4 2025, Return on Sales rose 104.0% year-over-year to 0.12%; the TTM value through Dec 2025 reached 0.42%, up 69.0%, while the annual FY2025 figure was 0.39%, 67.0% up from the prior year.
  • Return on Sales reached 0.12% in Q4 2025 per NVAX's latest filing, up from 2.87% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.78% in Q1 2025 and bottomed at 3.81% in Q4 2021.
  • Average Return on Sales over 5 years is 1.01%, with a median of 0.66% recorded in 2023.
  • Peak YoY movement for Return on Sales: surged 716bps in 2021, then plummeted -392bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 3.81% in 2021, then soared by 87bps to 0.51% in 2022, then dropped by -20bps to 0.61% in 2023, then plummeted by -50bps to 0.92% in 2024, then soared by 113bps to 0.12% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.12% in Q4 2025, 2.87% in Q3 2025, and 0.61% in Q2 2025.